Clovis Oncology, Inc. (CLVS)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
| Previous close | 1.4500 |
| Open | 1.4900 |
| Bid | 1.4700 x 1800 |
| Ask | 1.4900 x 3200 |
| Day's range | 1.4501 - 1.5500 |
| 52-week range | 0.5800 - 5.0000 |
| Volume | |
| Avg. volume | 12,857,212 |
| Market cap | 213.83M |
| Beta (5Y monthly) | 0.43 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.0840 |
| Earnings date | 01 Nov 2022 - 07 Nov 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 2.00 |
- Motley Fool
Why Clovis Oncology Stock Is Sinking Today
Shares of the cancer drugmaker Clovis Oncology (NASDAQ: CLVS) are under pressure yet again today. After this latest dip, Clovis' stock is down by over 46% for the year. The biotech released its 2022 second-quarter earnings report ahead of the opening bell Monday morning, and its latest financial results aren't a hit with shareholders.
- Zacks
Clovis (CLVS) Q2 Loss Wider Than Expected, Revenues Miss
Clovis (CLVS) incurs a wider-than-estimated loss in second-quarter 2022. Sales of the sole marketed drug Rubraca decline year over year due to COVID-19 impacts. CLVS faces the risk of a cash crunch.
- Zacks
Clovis Oncology (CLVS) Reports Q2 Loss, Misses Revenue Estimates
Clovis (CLVS) delivered earnings and revenue surprises of -2.38% and 15.01%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
© 2022 Yahoo. All rights reserved.
